Magnolia Medical Technologies articles

As a professor in infectious disease and microbiology, epidemiologist, and Medical Director of Infection Prevention and Control at Stanford Health Care, Dr. Lucy S. Tompkins was skeptical that a 0% blood culture contamination rate could be achieved, especially in a major academic medical center.

Study Results

In an oral abstract of the Steripath Gen2 Initial Specimen Diversion Device® (ISDD) study results presented to PACCARB 2021, the Preside

Improve sepsis testing accuracy. Enhance patient safety. These are the driving forces behind Magnolia Medical Technology’s Mission to ZERO.

Mission to ZERO™ is a nationwide plan to create greater awareness of patient safety and antibiotic-associated risks caused by false-positive diagnostic test results for sepsis. The goal is to initiate change by improving national blood culture guidelines and contamination